CN103315947A - 一种注射用替加环素组合物 - Google Patents
一种注射用替加环素组合物 Download PDFInfo
- Publication number
- CN103315947A CN103315947A CN2012100785099A CN201210078509A CN103315947A CN 103315947 A CN103315947 A CN 103315947A CN 2012100785099 A CN2012100785099 A CN 2012100785099A CN 201210078509 A CN201210078509 A CN 201210078509A CN 103315947 A CN103315947 A CN 103315947A
- Authority
- CN
- China
- Prior art keywords
- tigecycline
- injection
- injection compositions
- arginine
- prescription
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960004089 tigecycline Drugs 0.000 title claims abstract description 152
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 238000002347 injection Methods 0.000 title claims abstract description 45
- 239000007924 injection Substances 0.000 title claims abstract description 45
- FPZLLRFZJZRHSY-HJYUBDRYSA-N tigecycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O FPZLLRFZJZRHSY-HJYUBDRYSA-N 0.000 title claims abstract 34
- 239000003381 stabilizer Substances 0.000 claims abstract description 10
- 229930064664 L-arginine Natural products 0.000 claims description 50
- 235000014852 L-arginine Nutrition 0.000 claims description 50
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 48
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 38
- 239000011780 sodium chloride Substances 0.000 claims description 17
- 239000012530 fluid Substances 0.000 claims description 16
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 239000003085 diluting agent Substances 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 7
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims description 5
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 229940110377 dl- arginine Drugs 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 239000001540 sodium lactate Substances 0.000 claims description 5
- 229940005581 sodium lactate Drugs 0.000 claims description 5
- 235000011088 sodium lactate Nutrition 0.000 claims description 5
- 239000002253 acid Chemical group 0.000 claims description 4
- 239000003513 alkali Chemical group 0.000 claims description 4
- 239000007909 solid dosage form Substances 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 2
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims description 2
- 235000009697 arginine Nutrition 0.000 claims description 2
- 229960003121 arginine Drugs 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000003002 pH adjusting agent Substances 0.000 claims 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract description 17
- 239000008101 lactose Substances 0.000 abstract description 17
- 238000002360 preparation method Methods 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 6
- 238000010790 dilution Methods 0.000 abstract description 5
- 239000012895 dilution Substances 0.000 abstract description 5
- 230000008569 process Effects 0.000 abstract description 4
- 238000010525 oxidative degradation reaction Methods 0.000 abstract description 3
- 238000003860 storage Methods 0.000 abstract description 3
- 239000006260 foam Substances 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract 2
- 239000007788 liquid Substances 0.000 abstract 2
- 238000002474 experimental method Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- SOVUOXKZCCAWOJ-HJYUBDRYSA-N (4s,4as,5ar,12ar)-9-[[2-(tert-butylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O SOVUOXKZCCAWOJ-HJYUBDRYSA-N 0.000 description 118
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 43
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 42
- 238000012546 transfer Methods 0.000 description 38
- 238000005303 weighing Methods 0.000 description 38
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 14
- 229930195725 Mannitol Natural products 0.000 description 14
- 239000000594 mannitol Substances 0.000 description 14
- 235000010355 mannitol Nutrition 0.000 description 14
- 230000008901 benefit Effects 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 9
- 241000194017 Streptococcus Species 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 210000004907 gland Anatomy 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- KFTLBUWBQDMTSQ-JNCWMXRTSA-N (4s,4as,5ar,12ar)-4-(dimethylamino)-n-[2-(dimethylamino)acetyl]-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical class C1C2=CC=CC(O)=C2C(O)=C(C2=O)[C@@H]1C[C@@H]1[C@@]2(O)C(O)=C(C(=O)NC(=O)CN(C)C)C(=O)[C@H]1N(C)C KFTLBUWBQDMTSQ-JNCWMXRTSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 206010041925 Staphylococcal infections Diseases 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 229940101006 anhydrous sodium sulfite Drugs 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 229940001482 sodium sulfite Drugs 0.000 description 3
- 235000010265 sodium sulphite Nutrition 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000194032 Enterococcus faecalis Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940032049 enterococcus faecalis Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940040944 tetracyclines Drugs 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- UPLPHRJJTCUQAY-WIRWPRASSA-N 2,3-thioepoxy madol Chemical compound C([C@@H]1CC2)[C@@H]3S[C@@H]3C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 UPLPHRJJTCUQAY-WIRWPRASSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- 241000606123 Bacteroides thetaiotaomicron Species 0.000 description 1
- 241000606219 Bacteroides uniformis Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000588697 Enterobacter cloacae Species 0.000 description 1
- 241000588749 Klebsiella oxytoca Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 241001464887 Parvimonas micra Species 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010062255 Soft tissue infection Diseases 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940051497 arginine 1000 mg Drugs 0.000 description 1
- 229940086761 arginine 500 mg Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000005261 decarburization Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000006345 epimerization reaction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229940080839 methionine 500 mg Drugs 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000013094 purity test Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (16)
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210078509.9A CN103315947B (zh) | 2012-03-22 | 2012-03-22 | 一种注射用替加环素组合物 |
PL13763736T PL2881109T3 (pl) | 2012-03-22 | 2013-04-07 | Kompozycja tygecykliny do wstrzykiwania |
EP13763736.9A EP2881109B1 (en) | 2012-03-22 | 2013-04-07 | Tigecycline composition for injection |
PT137637369T PT2881109T (pt) | 2012-03-22 | 2013-04-07 | Composição de tigeciclina para injeção |
PCT/CN2013/000397 WO2013139179A1 (zh) | 2012-03-22 | 2013-04-07 | 一种注射用替加环素组合物 |
ES13763736T ES2795421T3 (es) | 2012-03-22 | 2013-04-07 | Composición de tigeciclina para inyección |
RU2015100116A RU2015100116A (ru) | 2012-03-22 | 2013-04-07 | Тигециклиновая композиция для инъекции |
US14/413,854 US9855335B2 (en) | 2012-03-22 | 2013-04-07 | Tigecycline composition for injection |
CA2879383A CA2879383C (en) | 2012-03-22 | 2013-04-07 | Tigecycline composition for injection |
US15/823,010 US20180078646A1 (en) | 2012-03-22 | 2017-11-27 | Tigecycline composition for injection |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210078509.9A CN103315947B (zh) | 2012-03-22 | 2012-03-22 | 一种注射用替加环素组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103315947A true CN103315947A (zh) | 2013-09-25 |
CN103315947B CN103315947B (zh) | 2016-01-20 |
Family
ID=49185185
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210078509.9A Active CN103315947B (zh) | 2012-03-22 | 2012-03-22 | 一种注射用替加环素组合物 |
Country Status (9)
Country | Link |
---|---|
US (2) | US9855335B2 (zh) |
EP (1) | EP2881109B1 (zh) |
CN (1) | CN103315947B (zh) |
CA (1) | CA2879383C (zh) |
ES (1) | ES2795421T3 (zh) |
PL (1) | PL2881109T3 (zh) |
PT (1) | PT2881109T (zh) |
RU (1) | RU2015100116A (zh) |
WO (1) | WO2013139179A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140323443A1 (en) * | 2013-04-30 | 2014-10-30 | Fresenius Kabi Usa, Llc | Tigecycline formulations |
WO2015071299A2 (en) * | 2013-11-12 | 2015-05-21 | Galenicum Health S.L. | Stable pharmaceutical compositions |
EA036750B1 (ru) * | 2016-01-08 | 2020-12-16 | Гуфик Байосайенсиз Лимитед | Лиофилизированная парентеральная композиция тигециклина и способ ее приготовления |
US11654151B2 (en) * | 2019-10-21 | 2023-05-23 | Rk Pharma Inc. | Storage-stable ready-to-use formulations of tigecycline |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101152152A (zh) * | 2006-09-28 | 2008-04-02 | 南京华威医药科技开发有限公司 | 注射用替加环素组合物及其制备方法 |
CN102138925A (zh) * | 2010-01-29 | 2011-08-03 | 江苏正大天晴药业股份有限公司 | 替加环素组合物及其制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101354093B1 (ko) | 2005-03-14 | 2014-01-24 | 와이어쓰 엘엘씨 | 티게사이클린 조성물 및 이의 제조방법 |
US9107929B2 (en) * | 2008-05-01 | 2015-08-18 | Ranbaxy Laboratories Limited | Stable parenteral formulations of tigecycline |
CN101401812B (zh) | 2008-11-14 | 2011-03-23 | 江苏奥赛康药业有限公司 | 替加环素冻干粉针剂 |
CN101919816B (zh) * | 2010-07-02 | 2012-07-25 | 赵军旭 | 一种含有替加环素的注射用无菌分装制剂 |
US20140323443A1 (en) | 2013-04-30 | 2014-10-30 | Fresenius Kabi Usa, Llc | Tigecycline formulations |
-
2012
- 2012-03-22 CN CN201210078509.9A patent/CN103315947B/zh active Active
-
2013
- 2013-04-07 US US14/413,854 patent/US9855335B2/en active Active
- 2013-04-07 PL PL13763736T patent/PL2881109T3/pl unknown
- 2013-04-07 CA CA2879383A patent/CA2879383C/en active Active
- 2013-04-07 EP EP13763736.9A patent/EP2881109B1/en active Active
- 2013-04-07 ES ES13763736T patent/ES2795421T3/es active Active
- 2013-04-07 WO PCT/CN2013/000397 patent/WO2013139179A1/zh active Application Filing
- 2013-04-07 RU RU2015100116A patent/RU2015100116A/ru not_active Application Discontinuation
- 2013-04-07 PT PT137637369T patent/PT2881109T/pt unknown
-
2017
- 2017-11-27 US US15/823,010 patent/US20180078646A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101152152A (zh) * | 2006-09-28 | 2008-04-02 | 南京华威医药科技开发有限公司 | 注射用替加环素组合物及其制备方法 |
CN102138925A (zh) * | 2010-01-29 | 2011-08-03 | 江苏正大天晴药业股份有限公司 | 替加环素组合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
EP2881109B1 (en) | 2020-03-11 |
CN103315947B (zh) | 2016-01-20 |
PL2881109T3 (pl) | 2020-10-19 |
WO2013139179A1 (zh) | 2013-09-26 |
EP2881109A1 (en) | 2015-06-10 |
CA2879383A1 (en) | 2013-09-26 |
CA2879383C (en) | 2021-01-26 |
US20150190511A1 (en) | 2015-07-09 |
RU2015100116A (ru) | 2016-07-27 |
EP2881109A4 (en) | 2016-03-09 |
US9855335B2 (en) | 2018-01-02 |
PT2881109T (pt) | 2020-04-23 |
US20180078646A1 (en) | 2018-03-22 |
ES2795421T3 (es) | 2020-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI78236B (fi) | Foerfarande foer framstaellning av en frystorkad doseringsenhet av cis-platina (ii) diamindiklorid. | |
CN103315947B (zh) | 一种注射用替加环素组合物 | |
CN101209255B (zh) | 连翘酯苷注射制剂及其制备方法 | |
CN105434373A (zh) | 一种注射用奥拉西坦冻干制剂及其制备方法 | |
EP2887953B1 (en) | Improved daptomycin injectable formulation | |
CN102302462B (zh) | 一种盐酸吉西他滨冻干制剂 | |
CN101912361B (zh) | 一种盐酸头孢替安/无水碳酸钠药物组合物混悬注射剂及其新应用 | |
CN108601730A (zh) | 万古霉素的制剂 | |
CN107205974A (zh) | 一种磺酰胺类药物组合物 | |
CN104414977A (zh) | 一种注射用青蒿琥酯和l-精氨酸组合物及其制备方法 | |
CN101254174B (zh) | 一种含卡络磺钠的冻干粉针剂及其制备方法 | |
CN102697757B (zh) | 对羟基苄叉丙酮在制备预防和/或治疗脑病药物中的应用 | |
WO2015071299A2 (en) | Stable pharmaceutical compositions | |
CN101554368B (zh) | 一种室温稳定的注射用替曲朵辛组合物制剂 | |
CN103142507A (zh) | 一种注射用克林霉素磷酸酯制剂及其制备方法 | |
CN108289897B (zh) | 一种瑞马唑仑的药物组合物 | |
CN101129374B (zh) | 长春氟宁药物组合物及其制备方法与应用 | |
CN102525908B (zh) | 卡络磺钠药物组合物及其制备方法 | |
TWI824702B (zh) | 藥物製劑及其製備方法和用途 | |
CN103330932B (zh) | 一种米卡芬净或其盐的药物组合物 | |
CN1568975A (zh) | 一种抗生素冻干剂型的制备方法 | |
CN1131039C (zh) | 克拉霉素注射液的制备方法 | |
CN101697973A (zh) | 一种注射用头孢硫脒制剂及其制备方法 | |
US20200108010A1 (en) | Kit for preparing injectable carmustine solutions | |
CN102895656B (zh) | 一种含三磷酸腺苷辅酶胰岛素化合物药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190515 Address after: Room 304-12, 665 Zhangjiang Road, Shanghai Free Trade Pilot Area, 201210 Patentee after: Shanghai Huilun Pharmaceutical Technology Co.,Ltd. Address before: Room 650-10, Building No. 2, 351 Guoshoujing Road, Zhangjiang High-tech Park, Pudong New Area, Shanghai, 201203 Patentee before: SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190815 Address after: Room 650-10, Building No. 2, 351 Guoshoujing Road, Pudong New Area Free Trade Pilot Area, Shanghai, 201203 Patentee after: SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY Co.,Ltd. Address before: Room 304-12, 665 Zhangjiang Road, Shanghai Free Trade Pilot Area, 201210 Patentee before: Shanghai Huilun Pharmaceutical Technology Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: Room 650-10, Building No. 2, 351 Guoshoujing Road, Pudong New Area Free Trade Pilot Area, Shanghai, 201203 Patentee after: Shanghai Hui Bio Technology Co.,Ltd. Address before: Room 650-10, Building No. 2, 351 Guoshoujing Road, Pudong New Area Free Trade Pilot Area, Shanghai, 201203 Patentee before: SHANGHAI HUILUN LIFE SCIENCE & TECHNOLOGY Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 200241 floor 10, building 5, No. 525, Yuanjiang Road, Minhang District, Shanghai Patentee after: Shanghai Huilun Pharmaceutical Co.,Ltd. Address before: Room 650-10, building 2, 351 GuoShouJing Road, Pudong New Area pilot Free Trade Zone, Shanghai 201203 Patentee before: Shanghai Hui Bio Technology Co.,Ltd. |